Morpholino

MO1-arf6a,arf6b

ID
ZDB-MRPHLNO-120425-4
Name
MO1-arf6a,arf6b
Previous Names
  • MO1-arf6
  • MO1-arf6a
  • MOArf6-a (1)
Targets
Sequence
5' - GATCTTGGAAAGCATCTTCCCCATG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Translation-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-arf6a,arf6b
Phenotype
Phenotype resulting from MO1-arf6a,arf6b
No data available
Phenotype of all Fish created by or utilizing MO1-arf6a,arf6b
Phenotype Fish Conditions Figures
spinal cord apoptotic process increased process quality, abnormal tamalinkm12/km12 + MO1-arf6a,arf6b (AB) control Figure 6 with imageFigure 7 with image from Seo et al., 2022
spinal cord apoptotic process process quality, ameliorated tamalinkm12/km12 + MO1-arf6a,arf6b (AB) chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine Figure 7 with image from Seo et al., 2022
spinal cord neuron apoptotic, abnormal tamalinkm12/km12 + MO1-arf6a,arf6b (AB) control Figure 7 with image from Seo et al., 2022
neuron apoptotic process increased process quality, abnormal tamalinkm12/km12 + MO1-arf6a,arf6b (AB) control Figure 6 with image from Seo et al., 2022
oligodendrocyte apoptotic process increased process quality, abnormal tamalinkm12/km12 + MO1-arf6a,arf6b (AB) control Figure 6 with image from Seo et al., 2022
gall bladder phospholipid decreased amount, abnormal WT + MO1-arf6a,arf6b + MO1-man1a2 control FIGURE 4 with image from So et al., 2020
intestinal bulb decreased size, abnormal s870Tg + MO1-arf6a,arf6b standard conditions Fig. S8 with image from Ningappa et al., 2015
swim bladder absent, abnormal s870Tg + MO1-arf6a,arf6b standard conditions Fig. S8 with image from Ningappa et al., 2015
pancreas decreased size, abnormal s870Tg + MO1-arf6a,arf6b standard conditions Fig. S8 with image from Ningappa et al., 2015
cholangiocyte aggregated, abnormal s939Tg + MO1-arf6a,arf6b standard conditions Fig. 3 with image from Ningappa et al., 2015
bile ductule decreased length, abnormal um14Tg + MO1-arf6a,arf6b standard conditions Fig. 3 with image from Ningappa et al., 2015
bile canaliculus decreased length, abnormal um14Tg + MO1-arf6a,arf6b standard conditions Fig. 3 with image from Ningappa et al., 2015
cholangiocyte filopodium decreased length, abnormal um14Tg + MO1-arf6a,arf6b standard conditions Fig. 3 with image from Ningappa et al., 2015
cholangiocyte decreased amount, abnormal um14Tg + MO1-arf6a,arf6b standard conditions Fig. 3 with image from Ningappa et al., 2015
intrahepatic bile duct disconnected, abnormal s939Tg + MO1-arf6a,arf6b + MO1-man1a2 control FIGURE 4 with image from So et al., 2020
hepatocyte decreased functionality, abnormal gz15Tg; um14Tg + MO1-arf6a,arf6b chemical treatment: tyrphostin AG 1478 Fig. 5 with image from Ningappa et al., 2015
liver decreased size, abnormal gz15Tg; um14Tg + MO1-arf6a,arf6b standard conditions Fig. 2 with image from Ningappa et al., 2015
hepatocyte decreased functionality, abnormal gz15Tg; um14Tg + MO1-arf6a,arf6b standard conditions Fig. 2 with image from Ningappa et al., 2015
intrahepatic bile duct decreased amount, abnormal gz15Tg; um14Tg + MO1-arf6a,arf6b standard conditions Fig. 2 with image from Ningappa et al., 2015
intrahepatic bile duct development disrupted, abnormal gz15Tg; um14Tg + MO1-arf6a,arf6b chemical treatment: tyrphostin AG 1478 Fig. 5 with image from Ningappa et al., 2015
intrahepatic bile duct epithelial cell filopodium decreased mobility, abnormal s939Tg; um14Tg + MO1-arf6a,arf6b standard conditions Fig. S6 with image from Ningappa et al., 2015
spinal cord oligodendrocyte decreased amount, abnormal tamalinkm12/km12; ck1Tg + MO1-arf6a,arf6b (AB) control Figure 6 with image from Seo et al., 2022
spinal cord neuron grm5b expression increased amount, abnormal tamalinkm12/km12; km13Tg; nkuasgfp1aTg + MO1-arf6a,arf6b (AB) control Figure 7 with image from Seo et al., 2022
spinal cord neuron grm5a expression increased amount, abnormal tamalinkm12/km12; km13Tg; nkuasgfp1aTg + MO1-arf6a,arf6b (AB) control Figure 7 with image from Seo et al., 2022
Citations